Learn what a Bachem capital increase is, why the company issues new shares to fund peptide capacity, and how dilution affects existing shareholders.
A Bachem capital increase is the issuance of new Bachem Holding AG shares to investors in exchange for cash. The proceeds are normally earmarked for long-term manufacturing capacity — new plants, clean rooms, and equipment — rather than for day-to-day operations. The cost to existing owners is dilution: each old share represents a smaller slice of the company unless the holder subscribes to the new shares.
The bachem company was founded in 1971 and has grown into one of the largest independent peptide manufacturers in the world, which is why its equity decisions attract attention well beyond Switzerland. Below is how a capital increase works, why a contract manufacturer would use one, and what shareholders should check.
What a Capital Increase Actually Is
A capital increase means a company creates and sells new shares. The company receives the cash; the buyers receive ownership. Existing shareholders are usually offered preemptive rights, called subscription rights, so they can buy in proportion to what they already hold.
Swiss companies generally use one of three routes:
- Ordinary capital increase: shareholders approve the issuance at a general meeting, and subscription rights are typically granted.
- Authorized capital: the board already has shareholder approval to issue up to a defined number of shares without a new vote.
- Conditional capital: shares are reserved in advance to satisfy conversions, such as convertible bonds or employee programs.
Whatever the route, the headline figures are the subscription ratio (say, one new share for every ten held), the issue price, and the discount to the market price. The full package is always described in a bachem press release when a transaction is announced.
Why Bachem Would Raise Equity Instead of Borrowing
Bachem is a contract manufacturer, not a drug developer. It earns revenue by producing peptides and oligonucleotides for pharmaceutical and biotech customers, which means growth is physical: reactors, purification lines, quality labs, and trained staff. Those projects take years to build and years more to fill.
Demand for peptide-based medicines, including GLP-1 therapies, has pushed the entire industry to add capacity faster than normal. Bachem manufactures in Bubendorf, Switzerland, and Torrance, California, and any large expansion at those sites requires capital that a single year of operating cash flow cannot cover.
Equity has advantages for that kind of spending. It does not have to be repaid, it carries no interest, and it does not come with loan covenants. The price is that existing owners give up part of the company. Many CDMOs use a mix of equity, debt, and retained earnings rather than relying on one source.
Growth is not only about peptides. The bachem oligonucleotide business is expanding as nucleic acid therapies advance through clinical trials, and it competes for the same capital budget. Analysts often watch the bachem amino acids catalog and capacity announcements as early signals of future revenue.
How the Math Works for Existing Shareholders
Dilution is easy to model once you know the ratio. Suppose a company has 1,000 shares outstanding and issues 100 new shares, a 10% increase. An investor who owns 100 shares and subscribes to all 10 shares their rights allow keeps a 10% stake. An investor who ignores the offer still owns 100 shares, but those shares now represent 9.1% of the company.
| Investor | Shares before | Subscribes? | Shares after | Ownership before to after |
|---|---|---|---|---|
| Investor A | 100 of 1,000 (10%) | Yes, 10 new shares | 110 of 1,100 | 10.0% to 10.0% |
| Investor B | 100 of 1,000 (10%) | No | 100 of 1,100 | 10.0% to 9.1% |
Selling the rights instead of exercising them can offset part of that loss, since rights usually trade during the subscription window. A capital increase is not automatically bad news for a share price — the market reaction depends on what the money buys and how the price is set.
Capital Increase vs. Other Funding Options
| Funding option | Who provides the money | Effect on shareholders | Typical use |
|---|---|---|---|
| Capital increase | New and existing investors | Dilutes ownership, adds equity | New plants, large capacity projects |
| Bank loan or bond | Lenders | No dilution, adds fixed costs | Equipment, working capital |
| Retained earnings | The company itself | No dilution, slower | Incremental upgrades |
For a manufacturing business with multi-year build cycles, equity is often the only realistic way to fund a step-change in capacity without stretching the balance sheet.
What to Check Before and After a Raise
Terms matter more than headlines. A raise priced at a small discount to the market is far friendlier to existing holders than one priced at a deep discount, because the discount transfers value from non-participating owners to subscribers.
- Use of proceeds: capacity expansion is a different story from plugging a cash shortfall.
- Subscription ratio and price: these two numbers determine the size of the dilution.
- Record date and exercise window: miss the window and the rights may expire worthless.
- Quality capacity: pharmaceutical customers require a bachem coa for every lot, so quality systems scale along with the plants.
- Tax treatment: rules on subscription rights and dividends differ by country, so US holders should confirm the details with a tax professional.
Risks, Misunderstandings, and a Note on Peptides
Two myths are worth clearing up. First, a capital increase does not mean a company is in trouble; healthy manufacturers raise equity precisely because demand is outrunning capacity. Second, dilution is not a one-way loss — shareholders who subscribe keep their percentage, and the cash is supposed to generate returns that outweigh the smaller slice.
The real risks are execution and timing. Plants can be delayed, customer programs can be canceled, and capacity built for one product class can sit idle if demand shifts. That is why the size of a raise relative to a company's existing asset base is worth checking.
Nothing on this page is investment advice. On the science side, peptide medicines are prescription products, and research-grade peptides sold online are not FDA-approved for human use — if you have questions about any peptide product, talk to a healthcare professional.
Frequently Asked Questions
What does a Bachem capital increase mean for existing shareholders?
It means more shares exist, so each old share represents a smaller slice of the company unless the holder subscribes to the new shares. Subscription rights let existing owners buy in proportion to what they already hold, which protects their percentage if they participate. Shareholders who do nothing typically see their stake shrink by the size of the raise.
Why would Bachem issue new shares instead of borrowing money?
Equity does not have to be repaid and carries no interest, which suits long-lived assets like manufacturing plants that take years to generate revenue. Debt preserves ownership but adds fixed costs and covenants that can restrict a company during a downturn. For very large capacity programs, many manufacturers use a mix of both.
Is a capital increase bad news for a stock?
Not automatically. A raise can signal that management expects demand to exceed current capacity, which is generally a positive sign for a growing manufacturer. It becomes a concern when a company raises money to cover operating losses rather than to fund specific growth projects.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.